Drug Patents owned by Orphalan

1. Drug name - CUVRIOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10988436 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11072577 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 28, 2025

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in